Business Update

PanGenomic Health Retains UK Investor Relations Advisory Firm

April 6, 2023

VANCOUVER, BC, April 6, 2023 /CNW/ – PanGenomic Health Inc. (“PanGenomic” or the “Company”) (CSE: NARA) is pleased to announce that Yellow Jersey PR Limited (“Yellow Jersey”) has been retained to provide investor relations and digital marketing services (the “Services”). 

Under the terms of the agreement, Yellow Jersey will provide a combination of public relations,  investor relations advisory services, content development, web development, media buying and distribution, and campaign reporting at a monthly cost to the Company of £2,500 over an initial three-month period beginning April 5, 2023. Thereafter Yellow Jersey’s fee will increase to £3,250 per month, provided that if the engagement exceeds a maximum of 13 hours per month, Yellow Jersey will charge the Company at an equivalent hourly rate.  Additional hourly charges will also apply to supplementary services, including digital design work and urgent crisis communications work (crisis communications work at rate of £350 per hour).  Yellow Jersey’s engagement may be terminated upon the provision of three months prior written notice.  Yellow Jersey is arm’s length to the Company and does not currently own any securities of the Company.

Yellow Jersey is a full-service public relations and investor relations firm with offices in London, Leeds and Zurich, that specializes in marketing publicly listed companies in the UK and Europe.

About PanGenomic Health Inc.

PanGenomic Health Inc. is a precision health company that has developed a self-care digital platform to deliver personalized, evidence-based information about natural treatments. The Company’s initial focus is to support mental health. Registered as a British Columbia benefit company, PanGenomic’s mission is to promote and improve the health and wellness of people and society by providing a technology platform that identifies plant-based solutions tailored to the health profile of each individual.

For further information, please contact:

Jerry Lai
Investor Relations
PanGenomic Health Inc.
778 743 4642

Maryam Marissen
President & CEO
PanGenomic Health Inc.
778 743 4642

This news release includes certain statements that may be deemed “forward-looking statements”, including statements respecting the services to be provided by PanGenomic and the consideration to be paid to PanGenomic. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “would”, “project”, “should”, “believe” and similar expressions are intended to identify forward looking statements. Although PanGenomic believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because PanGenomic can give no assurance that they will prove to be correct. In particular, there is no assurance that MUJN Diagnostics and/or Hemex Health will be able to develop the diagnostic decision support system or other  planned diagnostic products within the timeframes expected, or at all. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this News Release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in PanGenomic’s disclosure documents which can be found under PanGenomic’s profile on

The Canadian Securities Exchange has neither approved nor disapproved the information contained herein and does not accept responsibility for the adequacy or accuracy of this news release.